中国临床药理学与治疗学2024，Vol.29Issue(6)：707-714,8.DOI:10.12092/j.issn.1009-2501.2024.05.013
抗VEGF及其受体分子靶向药物治疗肝癌机制的研究进展
Advances of VEGF signalling pathway in hepatocellular carcinomar in-vasion and metastasis and therapy
摘要
Abstract
ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.关键词
VEGF/VEGFR抑制剂/肝细胞癌/信号通路/免疫疗法Key words
VEGF/VEGFR inhibitors/hepatocellu-lar carcinoma/signalling pathway/immunotherapy分类
医药卫生引用本文复制引用
蓝雪灵,黄燕妮,朱敏敏,马平,董敏..抗VEGF及其受体分子靶向药物治疗肝癌机制的研究进展[J].中国临床药理学与治疗学,2024,29(6):707-714,8.基金项目
国家自然科学基金青年基金(81302859) （81302859）
广西自然科学基金面上(2021GXNSFAA196070,2018GXNSFAA050121) （2021GXNSFAA196070,2018GXNSFAA050121）
广西科技计划重点研发项目(2022AB14010) （2022AB14010）
防城港市科技计划重点研发项目(AB22013006) （AB22013006）
